www.klinickafarmakologie.cz / Klin Farmakol Farm 2023;37(1):40-43 / KLINICKÁ FARMAKOLOGIE A FARMACIE 43 KAZUISTIKA Subkutánní infliximab v léčbě ankylozující spondylitidy LITERATURA 1. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Annals of the Rheumatic Diseases Published Online First. 2022. doi: 10.1136/ard-2022-223296. 2. Urbánek K. Infliximab. Interní Med. 2017;19(1):42-46. 3. www.sukl.cz. 4. Korsten P, Strohmayer K, Baughman RP, Sweiss NJ. Refractory pulmonary sarcoidosis – proposal of a definition and recommendations for the diagnostic and therapeutic approach. Clin Pulm Med. 2016;23(2):67-75. 5. Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol. 2016;174(5):970-978. 6. Schwartzman S. Advancements in the management of uveitis. Best Pract Res Clin Rheumatol. 2016;30(2):304-315. 7. Westhovens R, Wiland P, Zawadzki M, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology (Oxford). 2021;60(5):2277-2287. doi: 10.1093. 8. Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CTP13 Maintenance in Inflammatory Bowel Disease. Gastroenterology. 2021;160(7):2340-2353. doi: 10.1053. 23. ČESKÁ KONFERENCE KLINICKÉ FARMAKOLOGIE 7.–9. září 2023 Teoretické ústavy LF UP v Olomouci
RkJQdWJsaXNoZXIy NDA4Mjc=